The University of Utah will manufacture certain materials derived from stem cells, as per the agreement.
The University of Utah Clinical Regenerative Medicine and Tissue Engineering director Amit Patel said they are expanding their relationship with BioRestorative Therapies and hope to assist the company in producing their stem cell derived materials.
BioRestorative Therapies chairman and CEO Mark Weinreb said the deal indicates the beginning of laboratory operations and expects additional research and clinical collaborations.
BioRestorative Therapies uses cell and tissue protocols involving a patient’s adult stem cells (non-embryonic), enabling them to undergo cellular-based treatments.